REFRACTORY IMMUNE-MEDIATED NECROTIZING MYOPATHY

Clinical trials for REFRACTORY IMMUNE-MEDIATED NECROTIZING MYOPATHY explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY IMMUNE-MEDIATED NECROTIZING MYOPATHY trials appear

Sign up with your email to follow new studies for REFRACTORY IMMUNE-MEDIATED NECROTIZING MYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Can engineered immune cells stop a rare muscle disease?

⭐️ CURE ⭐️ Not yet recruiting

This early-stage trial is testing whether a personalized cell therapy called Eque-cel can safely and effectively treat people with refractory immune-mediated necrotizing myopathy (IMNM), a severe autoimmune condition that causes muscle weakness and damage. The therapy involves re…

Matched conditions: REFRACTORY IMMUNE-MEDIATED NECROTIZING MYOPATHY

Phase: PHASE1, PHASE2 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: ⭐️ CURE ⭐️

Last updated Aug 09, 2026 00:00 UTC

REFRACTORY IMMUNE-MEDIATED NECROTIZING MYOPATHY

Get alerted when new REFRACTORY IMMUNE-MEDIATED NECROTIZING MYOPATHY trials appear

Can engineered immune cells stop a rare muscle disease?